Akums Drugs & Pharma has disclosed that it received an ESG rating of 63 for the Financial Year 2024-25, as intimated to the stock exchanges on 8th May, 2026. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

ESG Rating Details

The rating was assigned by NSE Sustainability Ratings & Analytics Limited (NSE Sustainability), a subsidiary of NSE Indices Limited and a registered ESG Rating Provider. The company has clarified that it did not engage NSE Sustainability for this rating, and the assessment was voluntarily conducted based on publicly available information.

Key details of the ESG rating disclosure are summarised below:

Regulatory Disclosure

The intimation was filed by Dharamvir Malik, Company Secretary & Compliance Officer of Akums Drugs and Pharmaceuticals Limited, on 8th May, 2026. The disclosure was addressed to the Listing Departments of both the National Stock Exchange of India Ltd. and BSE Limited, in compliance with applicable SEBI regulations. The full ESG rating is accessible on the NSE Sustainability platform at the link provided in the official communication.

Akums Drugs & Pharmaceuticals Limited has announced that its wholly-owned subsidiary Pure and Cure Healthcare Private Limited executed a lease deed for an industrial plot in Haridwar, Uttarakhand. The company informed stock exchanges about this corporate development under SEBI regulatory requirements on April 29, 2026.

Lease Agreement Details

The subsidiary executed the lease deed on April 28, 2026, for an industrial plot with strategic importance to its operations. The property specifications and location details are outlined below:

Business Rationale

According to the company's disclosure, the industrial plot acquisition is strategically positioned adjacent to Pure and Cure Healthcare's existing manufacturing facility in Haridwar. This proximity is expected to support and enhance the subsidiary's business operations, providing operational synergies and expansion capabilities.

Regulatory Compliance

The company fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Dharamvir Malik signed the intimation letter sent to both National Stock Exchange of India Limited and BSE Limited, ensuring proper regulatory compliance for this corporate action.

The lease execution represents a strategic infrastructure expansion for the pharmaceutical company's subsidiary, strengthening its operational footprint in the Haridwar industrial corridor.